菜单
Generate comprehensive compound profiles including structure, properties, bioactivity, and development status. Use for drug analysis, SAR studies, and competitive profiling. Keywords: compound, drug, molecule, structure, SMILES, bioactivity, IC50
用 Codex 或 Claude 帮你安装 复制这段 Prompt，粘贴到 Codex、Claude 或其他助手里，让它检查 Skill 页面并帮你完成安装。
基于 SOC 职业分类
| name | compound-profile |
| description | Generate comprehensive compound profiles including structure, properties, bioactivity, and development status. Use for drug analysis, SAR studies, and competitive profiling. Keywords: compound, drug, molecule, structure, SMILES, bioactivity, IC50 |
| category | Compound Analysis |
| tags | ["compound","drug","structure","bioactivity","chembl"] |
| version | 1.0.0 |
| author | Drug Discovery Team |
| dependencies | ["chembl-database","pubchem-database","drugbank-database"] |
Comprehensive compound analysis for drug discovery and medicinal chemistry.
/compound erlotinib
/compound-profile CC1=CC=C(C=C1)CNC(=O)C1=NC=C(C=C1)N
Analyze osimertinib properties and bioactivity
Compare gefitinib, erlotinib, afatinib profiles
| Section | Description | Data Source |
|---|---|---|
| Basic Info | Name, type, status, company | ChEMBL, DrugBank |
| Structure | SMILES, InChI, molecular weight | PubChem, ChEMBL |
| Properties | LogP, HBD, HBA, TPSA, RO5 | Calculated, PubChem |
| Bioactivity | Target affinity, IC50, Ki | ChEMBL, BindingDB |
| Development | Phase, indications, status | Drugs@FDA |
| Similar Compounds | Structure similarity search | ChEMBL |
| Safety | Known toxicity, warnings | SIDER, PubChem |
# Compound Profile: Erlotinib
## Executive Summary
Erlotinib is a first-generation EGFR TKI approved for NSCLC (2004).
Key characteristics: Oral bioavailability, good brain penetration,
resistance mutations limit long-term efficacy.
## Basic Information
| Field | Value |
|-------|-------|
| Name | Erlotinib |
| Brand Names | Tarceva |
| ChEMBL ID | CHEMBL880 |
| Type | Small molecule |
| Class | Kinase inhibitor |
| Status | Approved |
| Approval Year | 2004 |
| Company | Astellas (OSI) |
| Indications | NSCLC, pancreatic cancer |
## Structure & Properties
**SMILES:** `COc1cc2nc(Nc3ccc(Oc4ccc(O)cc4)cc3)nc2cc1OC`
| Property | Value | Rule of 5 Check |
|----------|-------|----------------|
| MW | 393.4 Da | ✓ (<500) |
| LogP | 3.1 | ✓ (<5) |
| HBD | 1 | ✓ (≤5) |
| HBA | 7 | ✓ (≤10) |
| TPSA | 76.3 Ų | ✓ (<140) |
| Rotatable Bonds | 6 | |
## Bioactivity
| Target | Type | Affinity | Units |
|--------|------|----------|-------|
| EGFR | IC50 | 0.5 | nM |
| ERBB2 | IC50 | 1200 | nM |
| LCK | IC50 | 5 | nM |
## Development History
| Year | Milestone |
|------|-----------|
| 2004 | FDA Approval (NSCLC) |
| 2005 | EMEA Approval |
| 2010 | Pancreatic cancer approval |
| 2011 | Generic launch (US) |
## Similar Compounds
| Compound | Similarity | Difference |
|----------|------------|------------|
| Gefitinib | 85% | Different core scaffold |
| Afatinib | 72% | Irreversible binder |
| Osimertinib | 68% | 3rd-gen, mutant-selective |
| Icotinib | 82% | China-approved analog |
## Safety Profile
**Common AEs:** Rash, diarrhea, fatigue, anorexia
**Boxed Warning:** Interstitial lung disease
**Contraindications:** Hypersensitivity to erlotinib
## Patent Status
| Patent | Number | Expiry |
|--------|---------|--------|
| Base patent | US5747498 | 2019 (expired) |
| Formulation | US6943129 | 2020 |
| Method of use | US6900221 | 2021 |
/compound erlotinib
/compound-profile sotorasib
/compound "CC1=CC=C(C=C1)CNC(=O)C1=NC=C(C=C1)N"
/compound-profile SMILES
Compare compounds erlotinib, gefitinib, afatinib
Analyze bioactivity across EGFR inhibitors
/compound erlotinib --focus properties
Analyze drug-likeness of this compound
Check Lipinski rule of 5 violations
# Fetch compound by name
python scripts/fetch_compound_data.py erlotinib --output compound.json
# Fetch by SMILES
python scripts/fetch_compound_data.py --smiles "CC1=CC=C..." -o data.json
# Similarity search
python scripts/fetch_compound_data.py --similar CHEMBL880 --threshold 0.7
# Bioactivity summary
python scripts/fetch_compound_data.py erlotinib --bioactivity -o activity.json
# Structure search
python scripts/fetch_compound_data.py --scaffold quinazoline --limit 20
pip install requests pandas rdkit
| Pitfall | Solution |
|---|---|
| Name ambiguity | Use ChEMBL ID when possible |
| Stereochemistry | SMILES may not capture isomerism |
| Outdated data | Check multiple sources |
| Salt forms | API may have multiple entries |
| Tautomerism | Different SMILES for same structure |
Global drug development pipeline tracking by disease, target, mechanism, or company. Use for competitive intelligence, opportunity identification, and trend analysis. Keywords: pipeline, drug development, clinical trials, R&D tracking, competitive landscape
Structure-based similarity search and scaffold analysis for drug discovery. Use for lead hopping, scaffold morphing, and chemical space exploration. Keywords: similarity search, scaffold hopping, chemical space, fingerprint, Tanimoto
Analyze target competitive landscape including existing drugs, pipeline companies, differentiation opportunities, and market maturity assessment. Keywords: target competition, landscape, differentiation, pipeline analysis, market share
Target safety assessment including known toxicities, essentiality, and off-target concerns. Use for early safety risk evaluation and target selection. Keywords: target safety, toxicity, essential gene, knockout, safety risks
Comprehensive target validation assessing druggability, disease association strength, tractability, and competitive landscape. Use for go/no-go decisions on target selection. Keywords: target validation, druggability, tractability, disease association, genetic validation
ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) prediction for drug candidates. Use for assessing drug-likeness, PK properties, and safety risks early in drug discovery. Keywords: ADMET, PK, toxicity, drug-likeness, DILI, hERG, bioavailability